Rhumbline Advisers Has $2.92 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Rhumbline Advisers grew its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 0.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,561 shares of the company’s stock after acquiring an additional 585 shares during the quarter. Rhumbline Advisers’ holdings in IDEAYA Biosciences were worth $2,919,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in IDYA. Allworth Financial LP lifted its position in shares of IDEAYA Biosciences by 800.0% in the third quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 800 shares in the last quarter. Covestor Ltd increased its stake in IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after buying an additional 922 shares during the last quarter. R Squared Ltd bought a new stake in IDEAYA Biosciences during the 4th quarter worth about $35,000. US Bancorp DE boosted its stake in shares of IDEAYA Biosciences by 67.2% during the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after buying an additional 689 shares during the last quarter. Finally, KBC Group NV boosted its stake in shares of IDEAYA Biosciences by 29.1% during the 3rd quarter. KBC Group NV now owns 2,274 shares of the company’s stock worth $72,000 after buying an additional 513 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on IDYA shares. Leerink Partnrs downgraded IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Stephens reissued an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA opened at $20.57 on Friday. The stock has a market cap of $1.80 billion, a PE ratio of -6.23 and a beta of 0.82. The firm has a 50-day moving average of $23.30 and a 200-day moving average of $28.65. IDEAYA Biosciences, Inc. has a 52-week low of $19.95 and a 52-week high of $47.72.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. As a group, analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.